Nurix appoints former Merck CMO Roy Baynes to board of directors

Nurix Therapeutics, Inc.

Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.
Received initial option for 50,000 shares vesting over 3 years; annual cash retainers of $50,000 (board) and $5,000 (committee).
Served on Medical Advisory Board since 2023; will advise on clinical development including NX-5948 for CLL.
No family relationships or material interests with directors/officers; standard indemnification agreement executed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.